The GYS1 Knockout CAL-27 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout population engineered for loss-of-function studies of the glycogen synthase 1 (GYS1) gene. This product consistsof a heterogeneous pool of cells carrying diverse CRISPR/Cas9-mediated disruptions at the GYS1 locus, abolishing GYS1 protein expression and enzymatic activity. Unlike clonally derived monoclonal knockout cell lines, this polyclonal format captures a broader representation of editing outcomes, reducing potential biases from single-cell cloning and providing a robust model for investigating glycogen metabolism in a cancer-relevant epithelial background.
The parental CAL-27 cell line is a well-characterized adherent epithelial line derived from a human tongue squamous cell carcinoma. It exhibits hallmark features of aggressive oral cancer, including dysregulated signaling networks and altered metabolic dependencies. CAL-27 cells are extensively employed in oncological research to model tumor cell proliferation, invasion, and metabolic reprogramming. Their use as a host for GYS1 disruption enables direct interrogation of glycogen synthase function within the context of oral squamous cell carcinoma, a disease where aberrant glycogen accumulation has been correlated with tumor progression and therapeutic resistance.
GYS1 encodes the rate-limiting enzyme for glycogen synthesis, catalyzing the incorporation of UDP-glucose into glycogen chains. Its activity is tightly controlled by insulin and nutrient-sensitive pathways: insulin receptor (INSR) signaling through PI3K and AKT phosphorylates and inhibits glycogen synthase kinase?3?? (GSK?3??), relieving inhibitory phosphorylation on GYS1 and promoting glycogen synthesis. Conversely, AMP-activated protein kinase (AMPK) and protein phosphatase 1 (PP1) counterbalance these inputs. GYS1 physically interacts with glycogenin, the primer for glycogen synthesis, and with PP1-targeting subunits PPP1R3A and PPP1R3C, which direct the PP1 catalytic subunit to dephosphorylate GYS1. Downstream, GYS1 activity depletes cytosolic UDP-glucose and drives glycogen accumulation, linking hormonal cues to carbohydrate storage.
In the CAL-27 oral cancer model, genetic ablation of GYS1 halts glycogen synthase activity, leading to a profound reduction in cellular glycogen stores. This metabolic bottleneck cripples the cell??s ability to buffer against glucose deprivation and may enhance sensitivity to energetic stress. Given that many cancers co?opt glycogen metabolism to support proliferation, survival under hypoxia, and resistance to chemotherapy, the GYS1 knockout polyclonal cells offer a physiologically relevant system to dissect how glycogen remodels metabolic adaptation and stress resilience in oral squamous cell carcinoma. The model also aids in evaluating whether GYS1 represents a tractable therapeutic target.
This product is ideally suited for mechanistic studies of glycogen metabolism in oral cancer, including assessments of tumor cell proliferation, metabolic reprogramming, and drug resistance. Typical experimental workflows encompass glycogen quantification via periodic acid?CSchiff (PAS) staining, immunoblot analysis of total and phospho-GYS1, glucose uptake assays, cell viability measurements under nutrient-limited conditions, and real-time metabolic flux analysis using Seahorse analyzers. Complementary gene expression profiling by RT?qPCR further characterizes pathway alterations. For detailed product information and technical inquiries, please contact Ascent Research.
